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Summary The effects of expression of human c-myc and both mutated (T24) and normal forms of human
Ha-ras-1 were studied in an aneuploid rat fibroblast line (208F). Mutated T24 Ha-ras was also studied in a
near-diploid cell derived from early passage Chinese hamster lung fibroblasts (CHL). In contrast to the
parental fibroblasts, cells expressing any of the human oncogenes engendered rapidly growing tumours in
immune-suppressed animals. Blood- and lymph-borne metastases were observed from both ras- and myc-
expressing cells. In general ras-expressing cells were more aggressive than those expressing myc. In the 208F
background, expression of c-myc was associated with an incidence of mitosis similar to that in tumours
expressing T24 Ha-ras, but incidence of single cell death by apoptosis was higher. Quantitatively, expression
of human oncogene mRNA was constant during growth in vivo, and similar to that sometimes observed in
human neoplasms. Of 9 endogenous proto-oncogenes, 7 showed no change in expression from the parental
fibroblasts, but c-abl and c-fos were strongly expressed in all cells expressing human ras or myc. Thus these
tumorigenic cells, although transfected with single human oncogenes, all expressed oncogenes with both
nuclear- and membrane-associated products.
There is much evidence that cellular oncogenes of the ras
and myc families play a role in carcinogenesis (reviewed by
Klein & Klein, 1986; Weinberg, 1985), but surprisingly little
is known of their contribution to the pathology of
established tumours, and in particular to features of malig-
nancy such as growth by infiltration or metastasis. In human
neuroblastomas, there is a suggestive but incomplete
correlation between aggressive clinical course and amplifi-
cation (with overexpression) of N-myc (Brodeur et al., 1984;
Rosen et al., 1986). High levels of ras expression occur
frequently in primary human neoplasms of many types
(Slamon et al., 1984; Spandidos & Agnantis, 1984;
Spandidos & Kerr, 1984; De Bertoli et al., 1985; Spandidos
et al., 1985b; Kurzrock et al., 1986) but there is no evidence
that this is necessary or sufficient for maintenance of the
malignant phenotype (Gallick et al., 1985; Williams et al.,
1985). Rodent fibroblasts in which expression of ras genes
(with or without mutational activation) has been induced in
vitro, do acquire metastatic ability, however, as judged by a
pulmonary embolisation assay (Muschel et al., 1985;
Thorgeirsson et al., 1985). Moreover, the metastatic pheno-
type appears almost immediately on expression of the
inserted ras genes (Bradley et al., 1986). Ras-expressing cells
develop a constellation of new features. Some of these could
be expected to favour autonomous growth, such as the
production of tumour growth factors (Ozanne et al., 1982;
Anzano et al., 1985; Pragnell et al., 1985; Spandidos, 1985;
Marshall et al., 1985) and release from pre-existing control
by exogenous trophic stimuli (Kasid et al., 1985; Racker et
al., 1985; Zahn & Goldfarb, 1986), whilst some correlate
strongly with invasive and metastatic ability, such as
increased sialylation of surface glycoproteins (Collard et al.,
1985). Ras gene expression, however, is also associated with
enhanced cellular capacity to act as a target for NK
cytocidal activity (Johnson et al., 1985; Trimble et al., 1986)
a feature likely to militate against successful metastasis
(Nicolson & Poste, 1983; Hanna & Schneider, 1983). Any
relationship between ras expression and metastatic capacity
is likely to be influenced in addition by as yet unknown
cellular factors since ras expression appears to have little to
do with metastatic potential in murine cell lines of melanoma
(Kris et al., 1985) or epithelial origin (Muschel et al., 1985).
Even in fibroblasts there is evidence that the induction of
metastatic potential by ras expression may be inhibited by
products of other genes (Pozzatti et al., 1986).
In this paper we observe the effect of human c-myc and
Ha-ras- 1 genes on early and late passage fibroblasts,
inoculated subcutaneously into immune-suppressed mice.
Expression of the oncogenes is ensured through their linkage
to strong viral transcriptional enhancer elements (Spandidos
& Wilkie, 1984; Spandidos, 1985). In particular we ask
whether the tumours containing these oncogenes differ in
their growth properties at the site of inoculation or in their
metastatic ability, whether the abilities to metastasise by
lymphatic and haematogenous routes are conferred together,
or independently of each other, and whether expression of
endogenous proto-oncogenes is altered.
Materials and methods
Cell lines
All cell lines were maintained in Dulbecco's modification of
minimum Eagle's medium (MEM), supplemented to 10%
with new-born calf serum and penicillin and streptomycin.
The genesis of the cell lines has been fully described
elsewhere (Spandidos & Wilkie, 1984). CHL cells derived
from early passage hamster fibroblasts, whereas the 208F cell
line originated from Fisher rat fibroblasts (Quade, 1979) and
is aneuploid in karyotype. From the 208F cell line 3
derivative lines were obtained through insertion of mutated
(T24) and non-mutated human Ha-ras-1 and human c-myc
genes in high expression vectors, by the calcium phosphate
transfection technique. A single derivative cell line from
CHL fibroblasts was also studied, containing the mutated
(T24) human Ha-ras-I gene (hereafter called simply T24 Ha-
ras). Each derivative line was expanded from a single clone.
A satisfactory myc-expressing CHL transfectant has not been
obtained. The plasmids used for transfection were pHOSTl,
pHO6Nl and pMCGM1, containing the entire T24 Ha-ras
gene, the entire normal human Ha-ras- 1 proto-oncogene,
and the entire human c-myc gene respectively (Spandidos &
Wilkie, 1984; Spandidos, 1985). In pHOSTl the ras gene is
situated adjacent to the SV40 early promoter-enhancer
sequence; in pHO6Nl, both SV40 and Moloney virus LTR
enhancers are present; whilst in pMCGM 1, the Moloney
virus LTR sequence is linked to the human myc gene. All
the plasmids contain the aminoglycoside phosphotransferase
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gene (aph), conferring resistance to geneticin (G418), which
was used in the initial selection of the lines.
Animals
Female CBA mice of around six weeks of age were rendered
incompetent immunologically by thymectomy followed by
whole-body radiation and treatment with cytosine
arabinoside by a modification of the method of Steel et al.
(1978) (Hay et al., 1985). CHL, 208F, and the derivative myc
and ras expressing lines were suspended in Dulbecco's PBS
at a concentration of 1-2x 108 ml-1, and inoculated sub-
cutaneously in volumes of 0.1 ml, either to the left groin or
the mid-dorsal region around 4 weeks after whole body
irradiation. The mice were observed for tumour development
and killed at times dictated by the following criteria:
tumours of over 1.0cm diameter, obvious illness, or the
passage of at least four weeks with no or slow tumour
development. Although these criteria are somewhat
divergent, they afforded a convenient way to gather tumours
of widely differing behaviour: the rapidly growing tumours
appeared within 1-2 weeks and were harvested within 1-3
weeks of injection, animals with slower growing tumours
could be observed for longer, and the longest periods of
observation were reserved for animals in which there was no
evidence of tumour development.
At autopsy, portions of the tumour, and the lungs, heart,
liver, kidneys, adrenals, retro-peritoneal lymph nodes, and
axillary lymph nodes were fixed in 4% neutral buffered
formaldehyde, and processed through paraffin for
preparation of sections stained by haematoxylin and eosin,
van Gieson's stain (for collagen), or Lison's alcian blue,
chlorantine fast red stain (for mast cells). Portions of the
rapidly growing tumours, and some normal tissue were also
snap-frozen in liquid nitrogen for RNA and protein analysis
and stored at -80°C.
Analysis of RNA
RNA was extracted from pellets of at least 108 cultured cells,
or from snap-frozen portions of tumours, by the guani-
dinium thiocyanate method (Chirgwin et al., 1979). After
repeated precipitation in ethanol, RNA was checked for
integrity by observation of discrete ribosomal RNA bands
on 1% agarose gels containing 6.8% formaldehyde (Maniatis
et al., 1982), and stained with ethidium bromide. For semi-
quantitative analysis of oncogene expression a spot
hybridisation assay was employed (Spandidos et al., 1981).
RNA (5,ug) was spotted on nitrocellulose filters and probed
with oncogene DNA, labelled by nick translation with 32P-
dCTP under the following hybridisation conditions: 50%
formamide, 2 x SSPE, 5 x Denhardt's solution, 200jgml- 1
sheared salmon DNA, 0.5% SDS at 40°C for 18-24h. After
washing to stringencies specified in the text, the filters were
exposed to Fuji-Rx film.
For quantitative estimation of Ha-ras and c-myc RNA,
dots containing 1, 5 and lOjg of total cellular or tumour
RNA were spotted, in triplicate, adjacent to serial dilutions,
also in triplicate, of known quantities of Ha-ras or c-myc
RNA, generated from the plasmids pSPHa-ras 2 and
pMC64-10 using SP6 RNA polymerase. Filters were probed
with nick translated T24 Ha-ras or c-myc sequences as
described above. Following hybridisation RNA spots were
cut from the nitrocellulose filter using a cork borer and the
amount of hybridised probe determined by liquid
scintillation. The mean value for each triplet of spots was
calculated and a standard curve plotted using the values
obtained for SP6-generated Ha-ras or c-myc RNA. The
quantity of Ha-ras or c-myc RNA present in 1, 5 or 1Opg of
total cellular or tumour RNA was determined by intra-
polation on this standard curve. Values thus obtained for
Ha-ras and c-myc RNA were corrected to compensate for
the presence of noncoding sequences in the SP6 generated
RNA. Such sequences account for approximately 50% of the
Ha-ras RNA and 75% of the c-myc RNA. The resulting
value was expressed as a percentage of total RNA or of poly
A' RNA (using the assumption that 2% of total RNA is
poly A' RNA).
Plasmids usedfor hybridisation probes and RNA calibration
All probes were purified linear DNA sequences, isolated
from their plasmid vectors by restriction enzyme cleavage
and separation on low melting temperature I % agarose gels
as described below. The ensuing list gives the designation of
plasmids used for preparation of hybridisation probes,
preceded by the gene sequence represented and followed in
brackets by the restriction enzyme fragment selected.
Human Ha-ras-1: pT24-C3 (Sacl 2.9 kb); human c-myc:
pMC41-Cl (EcoRI, Hind!!! 8.4kb); human Ki-ras-2: pSP3K
(EcoRI, HindIll 0.64kb); mouse muscle actin: pAM91(PstI,
1.1 kb); human rDNA: pHR (EcoRI, 6.7kb) (details of these
plasmids are given in Spandidos & Kerr, 1984).
v-abl: pSA-17 (Hindl!, Sac!, 1.9kb); v:fos: pfos-BS
(BamH1 Sall, 0.76kb); v-sis: pAT/sis (Pstl, 1.3 kb); v-fes:
pfes-3 (PstI, 0.5 kb); v-src: psrc EcoR!-B (EcoRI, 2.95 kb)
(all obtained from Dr Natalie Teich, ICRF Laboratories,
Lincolns Inn Fields, London).
int-2: pint-2f (EcoRI, Sac!, 0.6kb); v-myb: pmyb-KS (Sac!,
BamH1, 1.2 kb) (from Dr Gordon Peters, ICRF, London).
int-2: pint-2f (EcoRI, Sac!, 0.6kb); v-myb: pmyb-KS (Sacd,
BamH1, 1.2kb) (from Dr Gordon Peters, ICRF, London).
v-erb-B: pverb-B-DT (BamHl, 0.5kb) (from D. Tannahill,
Edinburgh University).
The plasmids pSPH-ras 2 and pMC64-10 were constructed
by insertion into the vector SP64 of (respectively) the 2.9kb
Sac! fragment of the human T24 Ha-ras gene (containing all
four coding exons) or the 8.4kb EcoRI/HindIll fragment of
the human c-myc gene (containing all three coding exons).
Oncogene RNA was generated by incubation with SP6
polymerase (Melton et al., 1984) under the conditions
recommended by the manufacturer (Bethesda Research
Laboratories(BRL), Paisley, Scotland).
Immunoblotting
Monolayers of cultured cells were detached by incubation in
phosphate buffered saline containing 0.02% EDTA, and
lysed in 100mM sodium chloride, 10mM Tris pH 7.5, 0.1%
SDS, 1% NP40. Portions of snap frozen tumour were
treated similarly. Electrophoresis in 15% polyacrylamide
gels, electrophoretic blotting on nitrocellulose, and immuno-
staining with Y13-259 (Furth et al., 1982) were conducted as
previously described (Robinson et al., 1986), but using an
alkaline phosphatase-streptavidin system (Blu-gene, BRL) to
detect the biotinylated second antibody.
Results
Pathology of'primary' tumours
A summary of the tumour development at the subcutaneous
injection sites is given in Table I. Animals injected in groin
and back showed similar features and are considered
together.
CHL cells without human oncogenes never produced
visible or palpable tumours, and on autopsy 5 weeks after
inoculation no abnormality was detected at the injection site.
208F cells, without human oncogenes, although reputedly
non-tumorigenic, consistently yielded small, slowly-growing
nodules, not exceeding 5mm diameter even after 5 weeks.
Histologically these were low grade fibrosarcomas, with few
mitotic figures. There was conspicuous collagen deposition
around and between the tumour cells, and mast cells of
presumed host origin were plentiful within the tumours. No
necrosis was observed within these tumours, but cells at the
tumour edge appeared to be infiltrating between adjacent
adipocytes (Figure 1A).Table I Pathology of fibroblast tumours expressing human oncogenes
Metastasis Metastasis
Transfected Mice Primary Regressing Progressive in lung in node Total Time metastases noted
Host cell onc injected tumours tumours tumours (L) (N) metastases (day after injection)
Hamster nil 4 0 (0%) 0 (0%) 0 (0o) 0 0 0
fibroblast
(CHL) T24 H-ras 16 16 (100%) 5 (31.3%) 11 (68.8%) 3 3 6 (37.5%) L: 8,13,13
N: 18,25,35
Rat nil 7 0 (0%)a 0 (0%) 0 (0%) 0 0 0
fibroblast
(208F) T24 Ha-ras 31 29 (93.5%) 5 (16.1%) 24 (77.40) 6 5 8 (25.8%) L: 8,11,11114,14 14
N: 11,11J14,14) 14J
Ha-ras-! 15 14 (93.3,/) 2 (13.3/) 12 (800),) 0 2 2 (13.3%) N: 12,12
c-n?yc 25 13 (52.0%)b 0 (0%) 13 (52%) 1 1 2 (8.0%)c L: 22
N: 67
All bracketed figures are percentages of total injected animals. aAs indicated in the text all animals showed small nodules at the injection site,
not exceeding 0.5cm in diameter; bTake rate differs significantly from rat fibroblast tumours bearing c-Ha-ras (P<0.01) or T24 Ha-ras
(P<0.0001; Fisher's exact test); cMetastasis rate differs significantly from rat fibroblast tumours bearing T24 Ha-ras if scored at 14 days,
whether all injected animals (P<0.01) or only those with primary tumours (P<0.05) are considered.
Figure 1 Growth and regression of rodent fibroblasts in immune suppressed mice. (a): An indolent s.c. nodule produced by
injection of the 208F aneuploid rat line. Infiltration between adipocytes is seen (arrow). (b) Nascent collagen fibres at the
membrane of CHL cells transfected with T24 Ha-ras. (c): Aggressive growth of 208F cells transfected with T24 Ha-ras. Muscle
fibres in process of destruction by the tumour are seen (arrows). (d): Fat necrosis at site of regressing tumour, after injection of
CHL cells transfected with T24 Ha-ras. (a, c, d x 160; H & E. b x 30,000; uranyl acetate and lead citrate).
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CHL cells bearing the T24 Ha-ras gene yielded rapidly
growing tumours in all animals, reaching diameters of over
1 cm within 2 weeks. The tumours infiltrated, and sometimes
ulcerated, the overlying skin but were tethered to underlying
connective tissue only rarely. Histologically these were
aggressive fibrosarcomas with a high mitotic rate and little
collagen between cells although nascent collagen bundles
were identified on electron microscopy (Figure 1B). Zones of
necrosis were conspicuous in the centre of the tumours but
mast cells were not identified. Cells at the tumour periphery
infiltrated around and within the striated muscle fibres of the
panniculus carnosus, apparently destroying them
(Figure IC). Infiltration into adjacent fat and around
epidermal appendages was also evident, but a mantle of
mononuclear cells of uncertain histogenesis was often
observed running circumferentially around the deep margin
of the tumour. Several tumours showed extensive infiltration
by neutrophil polymorphs, and regression was obvious in a
proportion harvested between 13 and 35 days. Histologically,
such clearly regressing tumours consisted of masses of fat
necrosis with heavy neutrophil polymorph infiltration
(Figure ID). Despite this evidence of regression in some
animals, the majority of tumour-bearing animals bore
progressively enlarging tumours at the time of autopsy.
208F cells bearing T24 Ha-ras genes produced rapidly
enlarging fibrosarcomas of similar morphology to the above
(Figure 2A) and with a similar proportion showing
regression. Similarly, 208F cells expressing the normal
human Ha-ras-1 gene produced rapidly growing, potentially
lethal tumours, although these showed less necrosis at similar
size than the tumours bearing the mutated oncogenes. 208F
cells bearing human c-myc also produced growing tumours,
but in a significantly smaller proportion of animals than
after injection of ras-bearing cells. In seven of the animals
the tumours were aggressive fibrosarcomas (Figure 2B), but
in the remaining six the morphology was intermediate
between this and the indolent pattern of 208F cells alone. All
these tumours were substantially larger than those produced
by 208F cells alone, as observed at autopsy at closely similar
times after inoculation. However, they grew less rapidly than
the more aggressive variants, reached smaller diameters at
the time of autopsy, and did not contain central necrotic
areas.
Oncogene expression in aggressivefibrosarcomas
Expression of c-myc, Ha-ras, and nine proto-oncogenes was
assessed in examples of the aggressive fibrosarcomas,
harvested within 2 weeks of inoculation (Table II and Figure
3). In tumours bearing the mutated human T24 Ha-ras gene,
Ha-ras transcripts were present at levels close to those in the
originally injected cells. Thus, in both CHL and 208F cells
containing the T24 Ha-ras gene, levels of transcript were
estimated at around 0.8% of total cellular mRNA, between
20- and 53-fold greater than the untransfected parent cells.
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Figure 2 Aggressive fibrosarcomas at site of injection of 208F
cells transfected with T24 Ha-ras (a) and c-myc (b). Numerous
mitotic figures are present in both, but in (b) apoptotic bodies
are also conspicuous (arrows), intimately admixed with the
dividing cells. ( x 500; H & E).
Figure 3 Hybridisation of 32P probes to RNA from parental
fibroblasts (CHL, 208F), their derivative cell lines in vitro (+T24
ras, +myc) and the tumours engendered by these (+T24 ras t,
+myct). Thirteen filters were prepared identically, by spotting
5 ig total RNA from the sources shown. The filters were also
spotted with 2ng plasmid DNA: for each filter the plasmid
contained the sequence to be used as hybridisation probe. After
hybridisation (as in Materials and methods), the filters were
washed twice in 2 x SSC, 0.1% SDS at 20°C and then for a
further 2h at 65°C in 0.1 x SCC, 0.1% SDS (filters 1, 2, 10, 13)
or in I xSSC, 0.1% SDS (filters 3 9, 11, 12). The lower
stringency was chosen for these latter filters to allow for the less
perfect homology between the probe and target sequences.
Radiographic exposure time was adjusted so that approximately
equal signals were obtained from the plasmid DNA spots, with
the exception of filter 12, which was exposed for the same time
as filter 13. These two filters were included to confirm that all
the spots were equally loaded in terms of total RNA.FIBROBLASTS EXPRESSING HUMAN MYC AND RAS ONCOGENES 255
Table II Quantitative expression of human oncogenes in fibroblasts
in vitro and in vivo
RNA source onc RNA
Inserted % Total
Cell onc Type RNA 0 mRNA
CHL in vitro nil Ha-ras 0.0003 0.013
CHL in vitro T24 Ha-ras Ha-ras 0.016 0.80
CHL in vivo T24 Ha-ras Ha-ras 0.015 0.75
208F in vitro nil Ha-ras 0.0009 0.045
208F in vitro T24 Ha-ras Ha-ras 0.018 0.90
208F in vivo T24 Ha-ras Ha-ras 0.017 0.85
208F in vitro nil myc 0.0006 0.03
208F in vitro c-myc myc 0.011 0.55
208F in vivo c-myc myc 0.009 0.45
Methods for calculating onc RNA as % total of mRNA, by
calibration versus purified onc RNA, are given in the text.
The aggressive fibrosarcomas which derived from 208F cells
bearing the human c-myc gene showed a similar pattern,
although the steady state levels of myc transcript were nearer
0.5% of total mRNA, around 18-fold more than the un-
transfected cells. 208F cells bearing the normal human Ha-
ras-1 gene were not studied quantitatively for oncogene
mRNA, but semiquantitative dot blots (not shown) indicated
that Ha-ras transcripts were rather more abundant than in
the cells expressing the mutated gene. Further, immunoblots
of extracts from these cells and the corresponding tumours
showed that the expressed p21ras had the faster electro-
phoretic mobility expected of the product of the normal gene
(Figure 4). The immunoblots also confirmed that the cells
bearing the normal human proto-oncogene expressed much
more p2lras than the parental fibroblasts (in which p2lras
was barely detectable by the methods used) and to at least as
great a degree as the cells expressing the T24 Ha-ras gene.
In contrast to these high levels of expression of the
inserted human oncogenes, several other oncogenes tested
(including src, erb-B, fJs, myb, int-2 and Ki-ras) showed low
or barely detectable levels of expression in the aggressive
tumours themselves, the cells transfected with human c-myc
and Ha-ras prior to animal injection, and the parental
untransfected cells (Figure 3). Moderate expression of c-sis
was observed in both parental fibroblast lines and their ras-
and myc-expressing derivatives. In contrast, substantially
elevated expression of abl and fos was noted in the trans-
fected cells relative to both their parental untransfected
fibroblasts, regardless of whether the transfected gene was
human c-myc or T24 Ha-ras.
Metastasesfrom ras- and myc-expressing tumours
In around one third of animals in which tumours expressing
T24 Ha-ras grew at the inoculation site, there was evidence
of either blood- or lymph-borne metastasis (Table I). Blood-
borne metastases were all observed within 14 days, as were
the majority of the lymphatic metastases. Of the animals
injected with cells expressing normal human Ha-ras-1, two
developed metastases, both in lymph nodes, but these also
were detected within 14 days of injection. Of the 13 animals
in which myc-expressing cells produced a progressively
growing 'primary' tumour, two showed metastases, one by
lymphatics, the other (presumably haematogenous ) in the
lung. In one of these animals the 'primary' tumour showed
the aggressive type of histology. The total number of animals
with metastatic tumours was small, and the lower overall
yield with myc-expressing tumours, although suggestive, is
3 4 5 6 1 2 3 4 5 6
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Figure 4 Polyacrylamide gel electrophoresis of proteins from fibroblasts growing in vitro and in vivo. The left hand panel is a
kenacid-stained gel, the right hand an immunoblot of a similarly-loaded gel, incubated with the anti p2lras monoclonal Y13 259,
and detected with alkaline phosphatase linked to streptavidin-biotin complex. The tracks show proteins from (1) 208F cells
transfected with normal human Ha-ras-l, growing in vivo as an aggressive tumour, (2) 208F cells transfected with T24 Ha-ras, in
vivo, (3) CHL cells, with T24 Ha-ras, in vitro, (4) untransfected parental 208F cells, (5) as (1) but growing in vitro, (6) as 2, but in
vitro. The mobility of mol. wt standards is shown on the right. Both in vitro and as a tumour in vivo, 208F with normal Ha-ras-l
appears to express slightly more p2la. than 208F with T24 Ha-ras.256 A.H. WYLLIE et al.
not statistically significant. Nonetheless, the metastases in
both animals with myc-expressing secondary tumours were
detected substantially later than all the metastases from ras-
expressing tumours by the corresponding route. If metastases
detected by two weeks only are considered, the difference in
incidence between T24 Ha-ras and c-myc expressing tumours
is significant (Table I).
Morphologically, blood-borne metastases from the ras-
bearing tumours had similar morphology, regardless of
whether the original transfected cell was of CHL or 208F
type. Such metastases were found only in the lung, and
clearly emanated from small branches of the pulmonary
artery, filled with tumour cells (Figure 5A). Lymphatic
metastases were found in the para-iliac and para-aortic
nodes in animals injected subcutaneously in the groin, and in
the axillary nodes in animals injected in the back. The
affected lymph nodes were usually entirely occupied by
tumour cells, but in some there was evidence of partial
colonisation, commencing in the subcapsular sinus
(Figure SB).
In the single example of lymphatic metastasis from myc-
expressing 208F cells, the histology was similar to that in the
ras-expressing tumours, but the pulmonary metastasis was
unusual: a single small intra-pulmonary tumour nodule was
associated with malignant pleural effusion.
Figure 5 Spread of 208F cells expressing T24 Ha-ras to distant
sites. (a). Metastasis in small peribronchial vessels in lung. (b).
Growth in subcapsular sinus of lymph node. (x 160; H & E).
Cell turnover in aggressive myc- and Ha-ras-expressing
tumours
The small nodules engendered by 208F cells, and the rapidly
growing tumours of 208F cells expressing human myc and
ras, were studied histologically in more detail, in order to
compare the effects of oncogenes on patterns of cell turnover
in these tumours (Figure 6). Mitotic and apoptotic cells were
counted within the clearly viable, non-necrotic regions,
avoiding any areas in which infiltration by inflammatory
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Figure 6 Incidence of mitosis (0) and apoptosis (0) in the
viable portions of tumours expressing normal human Ha-ras-1,
T24 Ha-ras, and c-myc, or in the nodules engendered by the
parental 208F fibroblasts. All tissues were harvested between 9
and 21 days after injection, with the exception of the 208F
nodules marked *-, O-, which were harvested at 33 days. For
each animal the mean incidence of mitosis and apoptosis in 10
high power fields was measured. There are significant differences
in incidence of mitosis between Ha-ras-l and both T24 Ha-ras
and c-myc tumours (P<0.001; Student's t test). Significant
differences in incidence of apoptosis exist between T24 Ha-ras
and both Ha-ras-I and c-myc tumours (P<0.001) and also
between Ha-ras-l and c-myc tumours (P<0.02).
cells or extravasation of red cells was conspicuous. In the
small, indolent fibrosarcomas engendered by 208F cells alone
mitotic rates were consistently low. In animals killed at 33
days single cell loss by apoptosis was also infrequent, but
larger numbers of apoptotic cells were observed in one animal
killed at 14 days. The oncogene-expressing tumours were
studied only at 9-14 days after injection. 208F cells bearing
T24 Ha-ras produced tumours with high mitotic rates (- 10
fold more than parental 208F cells at the same time after
injection) but low apoptotic rates. Tumours expressing the
normal Ha-ras-l gene had lower mitotic rates, but apoptosis
was more frequent. In the more aggressive c-myc expressing
tumours harvested at around the same time after injection
both mitotic and apoptotic rates were high.
Discussion
Several groups have reported the ability of ras genes (with
and without mutation) to confer metastatic activity on
fibroblasts (Spandidos & Wilkie, 1984; Thorgeirsson et al.,
1985; Muschel et al., 1985; Bradley et al., 1986; Liotta, 1986)
although the assays used have focussed almost exclusively on
haematogenous tumour spread. Here we present evidence
that high expression of the mutated T24 Ha-ras-1 gene
confers aggressive properties, to an indistinguishable degree,
on both early and late passage fibroblasts. High expression
of the normal human Ha-ras-I proto-oncogene is also as-
sociated with rapidly growing tumours capable of metastasis.
In contrast, high expression of myc, in late passage fibro-
blasts, is associated with tumours which grow less ag-
gressively as measured in terms of primary 'take' rate,
growth rate, histology at the injection site, and the speed of
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development and proportion of animals affected by
metastasis.
We have found no evidence that blood-borne and lym-
phatic metastases are differentially affected by myc or ras
genes. Clearly, this study carries the usual strictures on inter-
pretation of the metastatic process (Mareel & van Roy,
1986). Thus, although we attempted to inoculate cells into the
subcutaneous tissue spaces, we cannot exclude the possibility
that some cells entered damaged veins or lymphatics at the
time of injection, rather than entering these in the course of
tumour growth. It has frequently been argued, however, that
even should such direct implantation into vessels have
occurred, the development of tumours at distant sites still
depends upon many of the factors essential for bona fide
metastasis of true primary tumours (Nicolson & Poste, 1983;
Liotta, 1986).
In experiments of this design it is not possible to be
completely certain that expression of the inserted human
oncogene is solely responsible for the malignant phenotype
observed. One trivial explanation would be that the different
types of growth behaviour observed are entirely coincidental
features of the particular cell clones studied. This seems
improbable, as high expression of T24 Ha-ras engenders
tumours with rather similar behaviour in entirely different
lines - CHL and 208F in this study, and fibroblasts of other
origins elsewhere (Muschel et al., 1985; Bradley et al., 1986;
Pozzatti et al., 1986). A second possibility is that the new
cell behaviour appearing after transfection is due to the viral
enhancers in the transfected plasmids rather than the
oncogenes themselves. The role of enhancers in carcino-
genesis has been emphasised (Chichutek & Duesberg, 1986;
Lang & Spandidos, 1986). Control experiments have already
shown, however, that cells transfected with the enhancers but
not the oncogenes underwent senescence, demonstrated no
features of transformation in vitro, and apparently failed to
generate progressive tumours (Spandidos & Wilkie, 1984).
A third and less readily dismissed possibility is that the
aggressive features observed are due to genetic changes
related to the oncogene expression only in a permissive sense,
but occuring during the process of selection for growth in
vitro and in vivo. Substantial cell selection necessarily occurs
between the time of transfection and animal inoculation.
There is also good evidence that growth of inoculated cells
in vivo can be associated with major changes in phenotype
(Nicolson & Poste, 1983) and oncogene arrangement (Winter
& Perucho, 1986). Karyotype analysis has shown that the
ras-expressing CHL cells show several chromosomal changes
as compared to the parent, untransfected cells which have
a normal, diploid karyotype (Spandidos et al., 1985a). The
208F karyotype is also hyperdiploid. However, ras-
expressing fibroblasts have been found to metastasise without
showing obvious progressive karyotypic changes in vivo
(Muschel et al., 1986), and we have confirmed here that
levels of expression of both the transfected oncogenes and
several proto-oncogenes remain remarkably constant during
the growth of aggressive fibrosarcomas in vivo.
It is of interest to compare the level of expression of myc
and ras genes in the transfected fibroblasts used here with
that in authentic human tumours. Although absolute values
of oncogene mRNA are seldom reported for the cells of
human tumours, the ratio of expression in neoplastic versus
control tissue is well documented. Thus myc expression may
show elevation in fresh leukaemic cells of 10-50 fold over
that in resting lymphocytes (Rothberg et al., 1984) and of 17
fold between the most and least expressing examples of
prostatic adenocarcinoma (Fleming et al., 1986). Even in the
course of non-neoplastic cell activation, myc expression may
rise up to 40 fold (Kelly et al., 1983). The myc expression in
our transfected fibroblasts of around 20 fold above the
parental level is thus well within this range. Increased
expression of ras, although usually at more moderate levels
in both neoplastic and normal cells (Goyette et al., 1983;
Slamon et al., 1984; Spandidos & Agnantis, 1984) has been
reported in benign colonic neoplasms as high as 30 fold
more than normal epithelium (Spandidos & Kerr, 1984).
An unexpected finding in this study was the observation
that c-abl and c-fos were highly expressed in fibroblasts
transfected with recombinant plasmids carrying the T24
Ha-ras or c-myc genes. To our knowledge this is the first
demonstration of alteration in expression of endogenous
c-oncs after insertion of extraneous oncogenes in high
expression vectors although accumulation of c-fos protein
has been induced in 3T3 fibroblasts by microinjection of
p2lras (Stacey et al., 1987). One implication of this obser-
vation is that all the tumorigenic cell lines investigated here
express oncogenes of both nuclear- and membrane-associated
groups (fos or myc and abl or ras). Hence the generalisation
that tumorigenicity requires co-activation of complementary
oncogene groups (Land et al., 1983; Ruley, 1983; Weinberg,
1985) may apply even to cells transfected with single extra-
neous oncogenes. We have no direct evidence on the nature
of the relationship between expression of the transfected myc
and ras genes and the activation of the endogenous c-abl
and c-fos. Enhanced expression of receptors for a or ,B TGF,
and increased release of TGFs, have been recorded in ras
and myc expressing cells however (Ozanne et al., 1982;
Heldin & Westermark, 1984; Anzano et al., 1985; Pragnell et
al., 1985; Spandidos, 1985), and activation of c-fos is known
to be dependent upon a wide spectrum of growth factors
(Kruijer et al., 1985; Colletta et al., 1986). It appears
unlikely that this activation of c-abt and c-fos could be solely
responsible for the aggressive growth of the transfected lines,
however, since levels of expression in the transfected cells,
were similar for both ras and myc bearing transfctants,
despite the differences in behaviour of these cells in vivo.
One outstanding difference between myc- and ras-
expressing tumours of otherwise similar histology was the
'disparity in their rates and modes of cell death. It has long
been appreciated that two contrasting modes of death can be
observed in tissues: necrosis, characterised by cell swelling
and rupture, and apoptosis, in which single cells shrink and
fragment, but retain intact membranes, and are subject to
phagocytosis by their viable neighbours (Kerr et al., 1972;
Wyllie et al., 1980). Zones of necrosis appeared in both
ras- and myc-expressing fibrosarcomas as they do in most
malignant tumours of man and animals. Although there is
much current interest in the cause of this, and a range of
explanations is offered, including lack of oxygen and nutrient
(Rotin et al., 1986), inadequate production of angiogenic
factors (Denekamp & Hobson, 1982; Folkman, 1986), or the
effect of tumour necrosis factors (Old, 1985; Klostergaard et
al., 1986), it is clear that in our material, necrosis of this
type appeared in the more aggressive fibrosarcomas rather
than the small, indolent ones, and bore no correlation with
other indices of aggression. In contrast, cell loss by apoptosis
within the viable portion of the tumour, which is also a
feature of most growing human and animal tumours (Wyllie,
1985), was much commoner (relative to mitosis) in myc-
expressing tumours as compared with the generally more
aggressive tumours expressing T24 Ha-ras. The tumours
expressing normal human Ha-ras-1 showed an intermediate
pattern. It has long been suspected that the high cell loss
rates observed in many growing animal and human tumours
may represent an intrinsically regulated process (Kerr et al.,
1972; Wyllie et al., 1980). We do not know what factors
within these tumours may be responsible, but it is interesting
to speculate that one of the results of expression of the
mutated Ha-ras oncogene may be to override the spontaneous
deletion of cells within tumour populations, and so perhaps
conserve cells with progressive deviation from normality.
In conclusion, high levels of expression of ras and myc
oncogenes in rodent fibroblasts are associated with a range
of new cellular features including aggressive growth,
characteristic patterns of cell turnover, and transcriptional
activation of endogenous proto-oncogenes. Several of these
features have no obvious immediate relationship with the258 A.H. WYLLIE et al.
known sites and modes of action of ras p21 products
(Wakelam et al., 1986) or the myc nucleoprotein (Rabbits,
1985). The dependence of these secondary features on the
high ras and myc expression can best be confirmed by use of
new plasmid constructs in which oncogene expression can be
modulated by extracellular agents, but the data presented
here are consistent with the view that biological aggressive-
ness may be the result of a constellation of cellular features,
engendered in different proportions by the products of
different oncogenes.
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